Mustang Bio MBIO Institutional Ownership

Ownership Summary

Mustang Bio, Inc. (NASDAQ:MBIO) showed up in the 13F filings of 22 institutional investors as of March 2026.

• These investors collectively held 7.5% of Mustang Bio's outstanding shares in March 2026, down from 11.2% in December 2025.
• They increased total shares held in Mustang Bio by 37.68% from last quarter, and the number of investors in MBIO increased 29.41% annually.
• During the quarter, 10 of these 22 funds increased positions in MBIO, 4 reduced exposure, and 8 held steady.
• Institutional investors collectively held 508.03K shares in Mustang Bio as of March 2026, up by 139.03K shares quarter on quarter, and up 348.46K shares year over year.
• As of March 31, 2026, Kestra Advisory Services, LLC held the largest stake in Mustang Bio with 176.04K shares, accounting for 2.62% of total shares outstanding.
• Leading buyers of Mustang Bio shares for the quarter ending March 2026 were Kestra Advisory Services, LLC (65.0K), GEODE CAPITAL MANAGEMENT, LLC (60.5K), VANGUARD FIDUCIARY TRUST CO (32.12K), VANGUARD CAPITAL MANAGEMENT LLC (25.7K), CFO4Life Group, LLC (7.5K).
• Top sellers of MBIO stock for the quarter ending March 2026 included CITADEL ADVISORS LLC (31.56K), TWO SIGMA INVESTMENTS, LP (23.28K), SBI Securities Co., Ltd. (1.5K), Morgan Stanley (35).
• Business Quant data shows the 10 biggest positions in Mustang Bio as of March 2026 are held by Kestra Advisory Services, LLC (176.04K), GEODE CAPITAL MANAGEMENT, LLC (92.79K), BlackRock, Inc. (84.74K), CITADEL ADVISORS LLC (53.2K), VANGUARD FIDUCIARY TRUST CO (32.12K), VANGUARD CAPITAL MANAGEMENT LLC (25.7K), CFO4Life Group, LLC (20.46K), TWO SIGMA INVESTMENTS, LP (16.75K), UBS Group AG (3.66K), Tower Research Capital LLC (TRC) (1.9K).